Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 11,581 shares of the company's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $47.70, for a total value of $552,413.70. Following the completion of the sale, the chief financial officer directly owned 54,084 shares in the company, valued at approximately $2,579,806.80. The trade was a 17.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Oluyemi Okupe also recently made the following trade(s):
- On Monday, July 7th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $46.67, for a total value of $540,485.27.
- On Monday, June 23rd, Oluyemi Okupe sold 23,107 shares of Hims & Hers Health stock. The stock was sold at an average price of $47.25, for a total value of $1,091,805.75.
- On Wednesday, May 28th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $52.98, for a total value of $613,561.38.
- On Thursday, May 15th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $60.22, for a total value of $697,407.82.
Hims & Hers Health Trading Up 1.7%
NYSE:HIMS traded up $0.87 during mid-day trading on Friday, hitting $50.86. 15,423,953 shares of the company's stock were exchanged, compared to its average volume of 24,085,393. The company has a 50 day simple moving average of $53.86 and a 200-day simple moving average of $41.62. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The firm has a market capitalization of $11.38 billion, a P/E ratio of 73.65, a PEG ratio of 1.91 and a beta of 2.02.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The firm had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The company's revenue for the quarter was up 110.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.05 EPS. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.
Institutional Trading of Hims & Hers Health
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Truist Financial Corp increased its stake in Hims & Hers Health by 20.7% during the 2nd quarter. Truist Financial Corp now owns 9,643 shares of the company's stock valued at $481,000 after purchasing an additional 1,656 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in shares of Hims & Hers Health by 15.1% in the 2nd quarter. Janney Montgomery Scott LLC now owns 10,019 shares of the company's stock worth $499,000 after acquiring an additional 1,311 shares in the last quarter. Signaturefd LLC grew its stake in shares of Hims & Hers Health by 36.6% in the 2nd quarter. Signaturefd LLC now owns 3,532 shares of the company's stock worth $176,000 after acquiring an additional 946 shares in the last quarter. ST Germain D J Co. Inc. bought a new stake in shares of Hims & Hers Health in the 2nd quarter worth $133,000. Finally, Dakota Wealth Management bought a new stake in shares of Hims & Hers Health in the 2nd quarter worth $354,000. Institutional investors own 63.52% of the company's stock.
Wall Street Analyst Weigh In
HIMS has been the subject of several recent research reports. Piper Sandler reiterated a "neutral" rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Wall Street Zen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. Truist Financial raised their price target on shares of Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a research note on Thursday. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a research report on Monday, June 23rd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $39.83.
View Our Latest Stock Analysis on Hims & Hers Health
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Further Reading
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access